[188 Pages Report] The Preclinical CRO Market size was estimated at USD 6.25 billion in 2023 and expected to reach USD 6.85 billion in 2024, at a CAGR 9.68% to reach USD 11.95 billion by 2030.
A preclinical CRO is a support center providing expertise in research and development activities (R&D) essential for navigating a drug candidate through animal testing and forwarding it into the clinical phase. Preclinical research services encompass several studies critical to assessing drug efficacy & safety in animal models and complete Investigational New Drug (IND) filing studies. In a preclinical trial, CROs are hired by sponsors such as biopharma companies to perform a set of tasks, taking various technical and administrative responsibilities on the sponsor’s behalf. A surge in the number of drugs in the preclinical phase and an increased research & development (R&D) budget for drug development are driving the usage of preclinical CRO services. The high cost and time-consuming process of preclinical CROS services hamper the market growth. Advances in technology, which include high-throughput screening and in silico modeling, enable more efficient and cost-effective preclinical research and are expected to create opportunities for market growth.
The unprecedented rise in non-communicable diseases among the geriatric population and communicable diseases caused by changing environmental conditions, such as pollution, and insect infestation, create a demand for effective drug development in the healthcare sector, subsequently increasing the need for preclinical CRO services across the Americas, Asia-Pacific, and EMEA. The investments made by the governments of Asia-Pacific to push research and development (R&D) activities of medical devices and drug development are estimated to provide growth opportunities for the preclinical CRO market players. In August 2021, the Australian government invested USD 79 million in medical innovation and research projects. The developed economies in the European Union have established a supportive government framework to boost technological advancements by prioritizing research and innovation of new technologies and drug development. The government introduces several stringent regulations and standards to ensure that the medicines and devices developed are safe, reliable, and of high quality. In January 2022, the Clinical Trials Regulation (Regulation (EU) No 536/2014) was set to launch in the EU to modify the clinical trial processes. The government introduced a Clinical Trials Information System (CTIS) to harmonize the supervision and assessment processes. Thus, the ongoing government support for clinical trials for medical devices and drug development is expected to fuel the growth of the preclinical CRO market in EMEA.
The market dynamics represent an ever-changing landscape of the Preclinical CRO Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
- Market Drivers
- Increasing R&D activities by pharmaceutical and biopharmaceutical companies to develop new drugs & therapies
- Rising trend of outsourcing drug development activities to CROs by pharmaceutical companies
- Growing focus on the development of personalized medicines
- Market Restraints
- High cost and time-consuming constraints associated with preclinical CRO services
- Market Opportunities
- Growing advances in technologies to enable more efficient and cost-effective preclinical research
- High potential for preclinical research for biologics, including monoclonal antibodies, vaccines, and cell therapies
- Market Challenges
- Stringent regulations and guidelines set by international regulatory authorities
Services: Burgeoning usage of Toxicology testing services focusing on the safety and regulatory compliance aspects
Bioanalysis and DMPK studies are crucial for understanding potential therapeutic agents' absorption, distribution, metabolism, and excretion (ADME) properties. This segment provides vital information on the drug's behavior in a biological system, which is paramount for dosage determination and safety assessment. These studies are preferred in the early stages of drug development when detailed insight into the drug's pharmacokinetic profile is required. Pharmaceutical companies and biotechnology firms often rely on external CROs with specialized expertise in bioanalytical methodologies and state-of-the-art technologies. Toxicology testing services are vital for evaluating the safety profile of drug candidates, ensuring they are safe for further development and human consumption. This segment encompasses a range of studies to assess the potential adverse effects of compounds on living organisms. These tests are critical before advancing to clinical trials, catering mainly to regulatory requirements that drugs must pass for approval. They are indispensable for all pharmaceutical and biotechnological companies needing to demonstrate the non-toxic nature of their products.
End-User: Evolving usage of preclinical CRO by biopharmaceutical companies
Biopharmaceutical companies are primary clients of preclinical CROs, leveraging their services for the development and testing of biologic drugs. These companies seek CRO partnerships to access specialized expertise in pharmacology, toxicology, and molecular biology. Services offered to biopharmaceutical companies often include drug efficacy and safety assessments, absorption, distribution, metabolism, excretion (ADME) studies, and regulatory support. Collaborating with preclinical CROs enables biopharmaceutical companies to accelerate their drug development process, manage costs effectively, and navigate complex regulatory requirements efficiently. Government and academic institutes often engage with preclinical CROs for research and development initiatives fundamental to public health objectives. These partnerships support projects, including new drug discoveries, vaccine development, and innovative medical treatments. Preclinical CROs provide these institutions with access to specialized resources and expertise that may not be available in-house. Additionally, CROs assist in conducting high-quality, regulatory-compliant research studies that can lead to groundbreaking medical advancements. Collaborations between government / academic institutes and CROs are pivotal in bridging the gap between basic research and clinical application. Medical device companies utilize preclinical CRO services to validate the security and efficacy of their products before proceeding to clinical trials. These companies benefit from CROs' technical and regulatory expertise to conduct comprehensive biomedical testing, biomechanical evaluation, and risk assessment. Services tailored to medical device companies often encompass preclinical study design, prototype testing, and support in complying with international standards and regulations. By partnering with CROs, medical device companies can assure their products meet the highest quality and safety standards, facilitating smoother transitions into clinical phases.
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Preclinical CRO Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Preclinical CRO Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Preclinical CRO Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the Preclinical CRO Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the Preclinical CRO Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Preclinical CRO Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Preclinical CRO Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Preclinical CRO Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the Preclinical CRO Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the Preclinical CRO Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Preclinical CRO Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Preclinical CRO Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
CRO Company TriApex Completes Series C Financing Round Led by Legend Capital
Triapex, a Preclinical CRO and Contract Research Organization (CRO), recently completed a Series C round of financing led by Legend Capital. This investment further strengthens Triapex's place among the top players in the global preclinical CRO market. With this additional funding, Triapex is well-positioned to provide high-quality services to its clients and expand its presence worldwide. The success of this financing round is a testament to Triapex's commitment to providing quality services through innovative methods, making them a preferred partner for many organizations. [Published On: 2023-05-05]
PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
PsychoGenics Inc., AI-enabled phenotypic drug discovery and preclinical CRO services provider, launched its advanced AI-Enabled Platform, eCube, to enable more efficient and effective preclinical drug discovery in the CRO market. eCube is the first data-driven platform that leverages Natural Language Processing (NLP) and Machine Learning algorithms to expedite the preclinical drug discovery process, which involves a large amount of manual labor. This revolutionary platform has been designed to streamline operations, reduce costs and optimize research timelines for various CROs in the preclinical market. With the help of eCube's comprehensive analytics system, CROs can generate meaningful insights from raw data for better decision-making. The launch of PsychoGenics' eCube marks a new era of innovation in the preclinical drug discovery process and promises to revolutionize the CRO market. [Published On: 2023-04-06]
Proscia Announces Major Expansion in Preclinical R&D to Drive Faster Drug Safety Decisions
The preclinical CRO market rapidly expands due to increased demand for drug safety decisions. Proscia recently announced a significant expansion into the preclinical research space, with plans to significantly increase their capabilities and expand their services. This move allows Proscia to continue providing innovative solutions that enable pharmaceutical companies and research institutions to make faster and better decisions about drug safety. With its new technology, such as advanced digital pathology and AI-driven image analysis, Proscia can offer unprecedented scalability, accuracy, and speed in preclinical research. This expansion is an essential step in helping the industry move forward in developing safer drugs with more reliable data. [Published On: 2023-03-20]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Preclinical CRO Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the Preclinical CRO Market, highlighting leading vendors and their innovative profiles. These include Phenos GmbH, Syneos Health, Inc., Eurofins Scientific SE, Jubilant Biosys Ltd. byJubilant Pharmova Limited Company, Parexel International Corporation., CTI Clinical Trial and Consulting, Inc., Shanghai Medicilon Inc., ICON PLC, Atuka Inc., Gubra, MCI Group Holding SA, SGS SA, Immusmol SAS, PsychoGenics Inc., Laboratory Corporation of America Holding, Hera Biolabs, IQVIA Inc., Biotrofix, Inc., Medpace Holdings, Inc., Veristat, LLC, Crown Bioscience, Inc., PharmaCircle LLC, PPD by Thermo Fisher Scientific Inc., Sanofi S.A., Celerion, BenchSci, SCiAN Services Inc., Vimta Labs Limited, Transpharmation, Diag2Tec SAS, MD Biosciences, ImQuest BioSciences, QPS Holdings, LLC, Invivotek by Genesis Biotechnology Group, LLC, Intertek Group PLC, WuXi AppTec Co., Ltd., 10x Genomics, Inc., Novartis AG, AmplifyBio, Charles River Laboratories International, Inc., F. Hoffmann-La Roche Ltd., Inotiv, Inc., and Bioserve Biotechnologies (India) PVT Ltd. by REPROCELL Inc..
This research report categorizes the Preclinical CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Services
- Bioanalysis & DMPK Studies
- Toxicology Testing
- Application
- Cardiovascular Disease
- Dermatology
- Gastrointestinal
- Genitourinary & Women’s Health
- Hematology
- Immunological Disorders
- Infectious Diseases
- Metabolic Disorders
- Neurology
- Oncology
- Ophthalmology
- Respiratory Disorders
- End-User
- Biopharmaceutical Companies
- Government & Academic Institutes
- Medical Device Companies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Preclinical CRO Market, by Services
- Preclinical CRO Market, by Application
- Preclinical CRO Market, by End-User
- Americas Preclinical CRO Market
- Asia-Pacific Preclinical CRO Market
- Europe, Middle East & Africa Preclinical CRO Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 22]
- List of Tables [Total: 302]
- List of Companies Mentioned [Total: 43]
Preclinical CROs are indispensable partners in the pharmaceutical industry today, as their experience, dedication, and efficiency for scientific rigor make them invaluable in developing new medications. Beyond traditional drug development, these CROs have honed their power in finding new therapies for rare diseases, gene therapy, and biologics.
Modern preclinical CROs have widely harnessed technology, with high throughput screening, data analytics, and machine learning now integral to their testing operations. Artificial intelligence (AI) has allowed the digitized preclinical trial process to be optimized and automated, and the preclinical CROs are well ahead in using them.
Preclinical CROs are also working on 3D cell culture models that give a more accurate assessment of drug candidates, particularly for oncology and tissue engineering applications. The immense interest in personalized medicine has made preclinical CROs tailor studies by using each individual's genetic makeup.
The ability of preclinical CROs to navigate through drug discovery and reduce production costs while ensuring the safety and efficacy of the drug, bringing the world closer to addressing some pressing issues and healthcare challenges of the future. As they push the boundaries of innovation, preclinical CROs hold promise for a brighter future for the medical research and development industry worldwide!
What is a preclinical CRO?
A preclinical CRO is a contracted research service provider that provides preclinical research services to pharmaceutical and biotechnology companies in drug discovery and development. Preclinical CROs conduct exploratory studies in living organisms to test the effectiveness and safety of potential drug candidates before progressing to clinical trial phases.
The benefits of outsourcing preclinical research:
Outsourcing preclinical research to CROs has become a popular tactic in the pharmaceutical industry. This is because it allows companies to focus on core competencies such as clinical development and commercializing drugs. Additionally, by outsourcing, companies can reduce their capital expenditures and overhead costs, which could otherwise be incurred from building and maintaining an internal preclinical research facility. CROs also offer diversified talent, expertise, and technical capabilities, meaning that pharmaceuticals save on recruitment, staff development, and training.
The services offered by preclinical CROs:
Preclinical CROs offer a wide range of services, including:
Lead optimization
Pharmacokinetic and toxicology studies
Bioanalysis
In vitro and in vivo studies
Behavioral studies
ADME assays/clinical chemistry assays
MRI and imaging services
Choosing the right preclinical CRO:
In selecting a preclinical CRO, pharmaceutical companies should consider factors such as the CRO's experience, infrastructure, and specialized capabilities in handling the specific type of study. The chosen CRO should have experience with animal models, strong study design, and analytical skills. It's always advisable to choose a preclinical CRO that specializes in the specific therapeutic area for the drug under investigation.
The future of preclinical CROs:
The preclinical CRO market is expected to grow due to increasing outsourcing trends. Companies continue to prefer third-party assistance over in-house capabilities, leading to a growing demand for preclinical outsourcing services. Increasing drug development complexity and advances in technology are also driving the growth of CROs, as companies require new technologies and skills that may not be available in-house.
Preclinical CROs play a crucial role in drug development, providing essential services that help pharmaceutical companies progress potential drug candidates toward treating diseases. Outsourcing preclinical research has become the norm in the pharmaceutical industry due to its cost-effectiveness and the ability to diversify expertise. As the pharmaceutical industry continues to adopt the use of CROs, the future of preclinical CROs is bright, providing them with opportunities for growth and continued market dominance. By carefully choosing the right preclinical CRO, pharmaceuticals can successfully conduct efficient and effective preclinical research.
- How big is the Preclinical CRO Market?
- What is the Preclinical CRO Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?